Advertisement
AMLX vs FENC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a StrongBuy and FENC is a Hold.
AMLX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for AMLX turned positive on October 20, 2026. Looking at past instances where AMLX's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMLX's RSI Indicator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on AMLX as a result. In 67 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
AMLX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in 233 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 189 of 218 cases where AMLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AMLX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.481) is normal, around the industry mean (6.379). P/E Ratio (-20.922) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
FENC in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
FENC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 39 cases where FENC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for FENC just turned positive on November 09, 2026. Looking at past instances where FENC's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
Following a +15.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in 203 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FENC as a result. In 93 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
FENC moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FENC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for FENC entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.105) is normal, around the industry mean (3.498). FENC has a moderately low P/E Ratio (-81.750) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.963) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FENC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
FENC | ||
|---|---|---|
OUTLOOK RATING 1..100 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 87 | |
SMR RATING 1..100 | 95 | |
PRICE GROWTH RATING 1..100 | 48 | |
P/E GROWTH RATING 1..100 | 44 | |
SEASONALITY SCORE 1..100 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AMLX | FENC | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 87% | N/A |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 79% |
| Advances ODDS (%) | 2 days ago 80% | 4 days ago 74% |
| Declines ODDS (%) | 18 days ago 81% | 8 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMLX’s FA Score shows that 0 FA rating(s) are green while FENC’s FA Score has 1 green FA rating(s).
- AMLX’s FA Score: 0 green, 5 red.
- FENC’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMLX’s TA Score shows that 6 TA indicator(s) are bullish while FENC’s TA Score has 3 bullish TA indicator(s).
- AMLX’s TA Score: 6 bullish, 3 bearish.
- FENC’s TA Score: 3 bullish, 5 bearish.
Price Growth
AMLX (@Pharmaceuticals: Generic) experienced а +8.16% price change this week, while FENC (@Biotechnology) price change was +2.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.93%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was +7.86%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.18%. For the same industry, the average monthly price growth was -2.37%, and the average quarterly price growth was -16.49%.
Reported Earning Dates
AMLX is expected to report earnings on Mar 09, 2027.
FENC is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (+1.93% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (+7.18% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AMLX and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMLX has been loosely correlated with OCUL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMLX jumps, then OCUL could also see price increases.
| Ticker / NAME | Correlation To AMLX | 1D Price Change % | ||
|---|---|---|---|---|
| AMLX | 100% | +2.88% | ||
| OCUL - AMLX | 46% Loosely correlated | +0.76% | ||
| LRMR - AMLX | 45% Loosely correlated | +1.49% | ||
| JAZZ - AMLX | 43% Loosely correlated | +1.14% | ||
| RGNX - AMLX | 43% Loosely correlated | +10.14% | ||
| IDYA - AMLX | 43% Loosely correlated | +3.04% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TSLP | 15.38 | 0.46 | +3.05% |
| Kurv Yield Prem Strategy Tesla ETF (TSLP) | |||
| USMF | 51.01 | 0.97 | +1.94% |
| WisdomTree U.S. Multifactor Fund (USMF) | |||
| IWB | 415.99 | 5.14 | +1.25% |
| iShares Russell 1000 ETF (IWB) | |||
| TEND | 27.78 | N/A | N/A |
| iShares Large Cap 10% Target Buffer Dec ETF (TEND) | |||
| FDD | 19.24 | -0.09 | -0.47% |
| First Trust STOXX European Select Dividend Income Fund | |||